Introduction: Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin's lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established.
Case Report: The authors report a case of a 62-year-old patient who developed widespread lichenoid eruption as a result of GA101 treatment for his follicular non-Hodgkin's lymphoma.
Conclusion: This is the first case report of cutaneous side effects of GA101.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510425 | PMC |
| http://dx.doi.org/10.1007/s13555-012-0003-9 | DOI Listing |
Publication Analysis
Top Keywords
ga101 novel
8
novel anti-cd20
8
anti-cd20 monoclonal
8
lichenoid eruption
8
ga101
4
monoclonal antibody-induced
4
antibody-induced lichenoid
4
eruption introduction
4
introduction obinutuzumab
4
obinutuzumab ga101
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!